Tag: tamoxifen

Articles

• Foods to eat and avoid during tamoxifen treatment
• Gynecological side effects of tamoxifen
• Impact of endocrine therapy (hormone therapy) on BC prognosis
• Tamoxifen and alcohol
• Tamoxifen and turmeric or curcumin supplements

News

05/28/23

Exposure to cadmium reduces effectiveness of tamoxifen

05/03/22

EGFR inhibition reduces resistance to tamoxifen treatment

05/12/21

Tamoxifen increases long-term survival in women with large tumor size

06/30/20

Failure to adhere to tamoxifen treatment reduces survival

06/24/17

EV olive oil suppresses ER+ growth & increases tamoxifen effectiveness

08/24/14

Exposure to light at night reduces tamoxifen effectiveness

07/31/13

Resveratrol enhances the treatment effects of tamoxifen

05/21/13

Reduction in breast density due to tamoxifen is favorable

05/07/13

Luteolin improves treatment in tamoxifen-resistant BC

02/22/13

Coffee may reduce risk of recurrence in tamoxifen-treated patients

12/09/12

Tamoxifen treatment for 10 years helps prevent late recurrence

04/19/12

Green tea polyphenol EGCG slows development of tamoxifen resistance

12/06/11

Red clover compound biochanin A reduces potency of tamoxifen in rats

07/17/11

Increasing aromatase inhibitor side effects make tamoxifen attractive

05/19/10

Omega-6 rich corn oil reduces effectiveness of tamoxifen

Studies

• Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy Cite
  Lee YJ, Noh WC, Gwark S, Kim H, Ryu JM, Kim SI, et al. Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01903-9
• Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018 Cite
  Bowles EJA, Ramin C, Vo JB, Feigelson HS, Gander JC, Veiga LHS, et al. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 208:577-587 10.1007/s10549-024-07453-0
• Impact of PEGylated liposomes on cytotoxicity of tamoxifen and piperine on MCF-7 human breast carcinoma cells Cite
  Vaiphei KK, Prabakaran A, Singh S, Murkute SL, Mohapatra P, Sahoo RK, et al. Impact of PEGylated liposomes on cytotoxicity of tamoxifen and piperine on MCF-7 human breast carcinoma cells. Journal of Drug Delivery Science and Technology. Elsevier BV; 2024;:106331 10.1016/j.jddst.2024.106331
• Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy Cite
  Ito M, Amari M, Sato A, Hikichi M, Tsurumi N, Otofuji H, et al. Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07509-1
• Effect of Protocatechuic Acid on Tamoxifen Efficacy and Oxidative Stress in Breast Cancer Cells: Implications for Combination Therapy. Cite
  Guneidy R, Shokeer A, Abdel karim GS, Saleh N, Zaki E. Effect of Protocatechuic Acid on Tamoxifen Efficacy and Oxidative Stress in Breast Cancer Cells: Implications for Combination Therapy.. Egyptian Journal of Chemistry. Egyptian Knowledge Bank; 2024; 67:167-181 10.21608/ejchem.2024.312360.10195
• Synergistic effect of curcumin and tamoxifen loaded in pH-responsive gemini surfactant nanoparticles on breast cancer cells Cite
  Ashin ZF, Sadeghi-Mohammadi S, Vaezi Z, Najafi F, AdibAmini S, Sadeghizadeh M, et al. Synergistic effect of curcumin and tamoxifen loaded in pH-responsive gemini surfactant nanoparticles on breast cancer cells. BMC Complementary Medicine and Therapies. Springer Science and Business Media LLC; 2024; 24 10.1186/s12906-024-04631-x
• Postmarketing adverse events of tamoxifen in male and female patients with breast cancer Cite
  Ke C, Chen M, Lin L, Huang Y. Postmarketing adverse events of tamoxifen in male and female patients with breast cancer. International Journal of Cancer. Wiley; 2024; 10.1002/ijc.35193
• Comparative study between effect of both drugs Tamoxifen versus Letrozole on endometrial thickness as Hormonal adjuvant therapy in breast cancer Cite
  Alsaadi KAJS, Zakria AM, Saeed AMM, Mohamed MS, Ghoneim WAW, Selim MM, et al. Comparative study between effect of both drugs Tamoxifen versus Letrozole on endometrial thickness as Hormonal adjuvant therapy in breast cancer. International journal of health sciences. Universidad Tecnica de Manabi; 2022;:11163-11175 10.53730/ijhs.v6ns6.13067
• Incidence of endometrial cancer in BRCA mutation carriers Cite
  Kotsopoulos J, Lubinski J, Huzarski T, Bychkovsky BL, Moller P, Kim RH, et al. Incidence of endometrial cancer in BRCA mutation carriers. Gynecologic Oncology. Elsevier BV; 2024; 189:148-155 10.1016/j.ygyno.2024.07.687
• The Impact of Tamoxifen Usage in Breast Cancer Patients on the Development of Histopathological Lesions in the Cervix Uteri Cite
  Cetin F, Kayar İ, Goc G, Birge Ö. The Impact of Tamoxifen Usage in Breast Cancer Patients on the Development of Histopathological Lesions in the Cervix Uteri. Medicina. MDPI AG; 2024; 60:1268 10.3390/medicina60081268
• Nano-enabled thermo-responsive local delivery of tamoxifen and carvacrol for enhanced anticancer action Cite
  Walke N, Aalhate M, Mahajan S, Singh H, Maji I, Gupta U, et al. Nano-enabled thermo-responsive local delivery of tamoxifen and carvacrol for enhanced anticancer action. Journal of Drug Delivery Science and Technology. Elsevier BV; 2024; 100:106013 10.1016/j.jddst.2024.106013
• Alzheimer Disease and Related Dementia Following Hormone-Modulating Therapy in Patients With Breast Cancer Cite
  Cai C, Strickland K, Knudsen S, Tucker SB, Chidrala CS, Modugno F. Alzheimer Disease and Related Dementia Following Hormone-Modulating Therapy in Patients With Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2024; 7:e2422493 10.1001/jamanetworkopen.2024.22493
• P-317 Risk of endometrial polyps and hyperplasia after tamoxifen treatment in women with breast cancer: a population-based study in Taiwan Cite
  Hsu C, Eing-Mei T, Hui-min H. P-317 Risk of endometrial polyps and hyperplasia after tamoxifen treatment in women with breast cancer: a population-based study in Taiwan. Human Reproduction. Oxford University Press (OUP); 2024; 39 10.1093/humrep/deae108.682
• Acupuncture for hot flashes in hormone receptor‐positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials Cite
  Lu W, Giobbie‐Hurder A, Tanasijevic A, Kassis SB, Park SH, Jeong YJ, et al. Acupuncture for hot flashes in hormone receptor‐positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials. Cancer. Wiley; 2024; 10.1002/cncr.35374
• Functional combination of resveratrol and tamoxifen to overcome tamoxifen‐resistance in breast cancer cells Cite
  Radwan AM, Abosharaf HA, Sharaky M, Abdelmonem R, Effat H. Functional combination of resveratrol and tamoxifen to overcome tamoxifen‐resistance in breast cancer cells. Archiv der Pharmazie. Wiley; 2024; 10.1002/ardp.202400261
• Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors Cite
  Chang C, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, et al. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. British Journal of Cancer. Springer Science and Business Media LLC; 2024; 130:1943-1950 10.1038/s41416-024-02680-0
• Efficacy of pre-surgical short-term endocrine therapy during the waiting period for surgery in post-menopausal hormone receptor-positive breast cancer Cite
  Maeda Y, Sato A, Matsumoto A, Ikeda T, Jinno H. Efficacy of pre-surgical short-term endocrine therapy during the waiting period for surgery in post-menopausal hormone receptor-positive breast cancer. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-4490367/v1
• Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer Cite
  Wang Y, Sun M, He Z, Han Y, Song Y, Liang J, et al. Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer. Heliyon. Elsevier BV; 2024; 10:e33104 10.1016/j.heliyon.2024.e33104
• A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors Cite
  Bright EE, Finkelstein LB, Nealis MS, Genung SR, Wrigley J, Gu HCJ, et al. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:4548-4561 10.1200/jco.23.00697
• Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression Cite
  Franceschi BT, Bezerra PHA, Torqueti MR. Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression. Breast Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s12282-024-01590-6
• 268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation Cite
  Dumas E, Hamy-Petit A, Gougis P, Laas E, El Ferjaoui S, Jochum F, et al. 268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation. ESMO Open. Elsevier BV; 2024; 9:103327 10.1016/j.esmoop.2024.103327
• Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial Cite
  Giacchetti S, Laas E, Bachelot T, Lemonnier J, André F, Cameron D, et al. Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial. eBioMedicine. Elsevier BV; 2024; 104:105141 10.1016/j.ebiom.2024.105141
• Abstract PO4-24-09: Grape seed extract inhibits EGFR signaling pathway as a main factor of tamoxifen resistant in hormone receptor positive breast cancer Cite
  Jung SP, Lee E, You JY, Chun JH, Kim H. Abstract PO4-24-09: Grape seed extract inhibits EGFR signaling pathway as a main factor of tamoxifen resistant in hormone receptor positive breast cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO4-24-09-PO4-24-09 10.1158/1538-7445.sabcs23-po4-24-09
• Abstract PO2-12-11: Ocular Toxicity of Tamoxifen in Patients with Breast Cancer Cite
  Alhouz H, Azmeh A, Saifo M. Abstract PO2-12-11: Ocular Toxicity of Tamoxifen in Patients with Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO2-12-11-PO2-12-11 10.1158/1538-7445.sabcs23-po2-12-11
• Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen? Cite
  Iatrakis G, Zervoudis S, Sarella A, Bothou A, Tsikouras P, Paschopoulos M, et al. Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?. Review of Clinical Pharmacology and Pharmacokinetics - International Edition. PHARMAKON-Press; 2024; 38:7-9 10.61873/oefm7580
• Abstract 992: The impact of tamoxifen on autophagic and epigenetic regulation in endometrial cancer Cite
  Thota S, Begum R, Chintala N, Pandit A, Sapkota B, Francis J. Abstract 992: The impact of tamoxifen on autophagic and epigenetic regulation in endometrial cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:992-992 10.1158/1538-7445.am2024-992
• The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation Cite
  Gomaa S, Lopez A, Slamon R, Smith R, Lapitan E, Nightingale G, et al. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation. Supportive Care in Cancer. Springer Science and Business Media LLC; 2023; 31 10.1007/s00520-023-08170-y
• Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer Cite
  Saeki H, Horimoto Y, Hlaing M, Men Y, Rong L, Ishizuka Y, et al. Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer. Oncology Letters. Spandidos Publications; 2023; 27 10.3892/ol.2023.14142
• Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy Cite
  Thomas NS, Scalzo RL, Wellberg EA. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nature Reviews Endocrinology. Springer Science and Business Media LLC; 2023; 10.1038/s41574-023-00899-0
• Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis Cite
  He P, Li J, Chen M, Huang M, Qiu Y, Cai Q, et al. Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07105-9
• Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer Cite
  Sasada S, Kondo N, Hashimoto H, Takahashi Y, Terata K, Kida K, et al. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 202:473-483 10.1007/s10549-023-07097-6
• Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events Cite
  Mitchell JM, DeLeire T, Isaacs C. Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events. Cancer. Wiley; 2023; 10.1002/cncr.35009
• Assessment of ultrasonographic endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients receiving tamoxifen as hormonal adjuvant therapy Cite
  Babin M, Gluck O, Yeruham I, Keidar R, Kerner R, Weiner E, et al. Assessment of ultrasonographic endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients receiving tamoxifen as hormonal adjuvant therapy. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3319956/v1
• Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis Cite
  Jordt N, Kjærgaard KA, Thomsen RW, Borgquist S, Cronin-Fenton D. Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07043-6
• The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy Cite
  Oner G, Broeckx G, Van Berckelaer C, Zwaenepoel K, Altintas S, Canturk Z, et al. The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy. Cancer Medicine. Wiley; 2023; 10.1002/cam4.6425
• Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients Cite
  He Y, Li Y, Geng Y, Liu A, Gao F, Ji C, et al. Prospective Exploratory Study of the Effects of Postoperative Endocrine Medication on the Endometrium in Breast Cancer Patients. International Journal of General Medicine. Informa UK Limited; 2023; Volume 16:3677-3687 10.2147/ijgm.s417965
• CBD-oil as a potential solution in case of severe tamoxifen-related side effects Cite
  Buijs SM, Braal CL, Buck SAJ, van Maanen NF, van der Meijden-Erkelens LM, Kuijper-Tissot van Patot HA, et al. CBD-oil as a potential solution in case of severe tamoxifen-related side effects. npj Breast Cancer. Springer Science and Business Media LLC; 2023; 9 10.1038/s41523-023-00570-x
• Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial Cite
  Baek SY, Noh WC, Ahn S, Kim H, Ryu JM, Kim SI, et al. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 10.1200/jco.23.00557
• Anti-proliferative, pro-apoptotic, and chemosensitizing effects of carthamus tinctorius (safflower) extract on breast cancer cell line Cite
  Rezazadeh D, Nemati H, Khani F, Darabi F, Jalili C. Anti-proliferative, pro-apoptotic, and chemosensitizing effects of carthamus tinctorius (safflower) extract on breast cancer cell line. World Cancer Research Journal. Verduci International LLC; 2023; 10 10.32113/wcrj_20237_2622
• Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation Cite
  Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, et al. Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad109
• Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation Cite
  Kotsopoulos J, Gronwald J, Huzarski T, Aeilts A, Randall Armel S, Karlan B, et al. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-06991-3
• The beneficial effects of tamoxifen on arteries: a key player for cardiovascular health of breast cancer patient Cite
  Davezac M, Meneur C, Buscato M, Zahreddine R, Arnal J, Dalenc F, et al. The beneficial effects of tamoxifen on arteries: a key player for cardiovascular health of breast cancer patient. Biochemical Pharmacology. Elsevier BV; 2023;:115677 10.1016/j.bcp.2023.115677
• Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women Cite
  Hammarström M, Gabrielson M, Crippa A, Discacciati A, Eklund M, Lundholm C, et al. Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 129:61-71 10.1038/s41416-023-02293-z
• Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review Cite
  Eliassen FM, Blåfjelldal V, Helland T, Hjorth CF, Hølland K, Lode L, et al. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11122-8
• Assessment of the Impact of Anti-Hormonal Treatment on Bone Health in Patients With Breast Cancer Using Machine-Learning Analysis Cite
  Park H, Park M, Kim K, Kang T. Assessment of the Impact of Anti-Hormonal Treatment on Bone Health in Patients With Breast Cancer Using Machine-Learning Analysis. Journal of Breast Disease. Korean Breast Cancer Society; 2023; 11:1-10 10.14449/jbd.2023.11.1.1
• Evaluation of endometrial thickness in breast cancer patients with tamoxifen treatment – Difference between 2-dimensional ultrasonography and elastosonography Cite
  Jo HB, Lee HJ, Kim SC, Joo JK, Suh DS, Kim KH. Evaluation of endometrial thickness in breast cancer patients with tamoxifen treatment – Difference between 2-dimensional ultrasonography and elastosonography. Taiwanese Journal of Obstetrics and Gynecology. Elsevier BV; 2023; 62:547-552 10.1016/j.tjog.2023.04.004
• Combination of tamoxifen and D-limonene enhances therapeutic efficacy in breast cancer cells Cite
  Mandal D, Sahu BR, Parija T. Combination of tamoxifen and D-limonene enhances therapeutic efficacy in breast cancer cells. Medical Oncology. Springer Science and Business Media LLC; 2023; 40 10.1007/s12032-023-02081-y
• Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study Cite
  Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:3116-3121 10.1200/jco.22.02900
• The Interplay between Microbiota and Chemotherapy-Derived Metabolites in Breast Cancer Cite
  Plaza-Diaz J, Álvarez-Mercado AI. The Interplay between Microbiota and Chemotherapy-Derived Metabolites in Breast Cancer. Metabolites. MDPI AG; 2023; 13:703 10.3390/metabo13060703
• Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial. Cite
  Giacchetti S, Laas E, Bachelot T, Lemonnier J, Andre F, Cameron DA, et al. Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:546-546 10.1200/jco.2023.41.16_suppl.546
• 94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis Cite
  Lammers S, Geurts S, van Hellemond I, Swinkels A, Smorenburg C, van der Sangen M, et al. 94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis. ESMO Open. Elsevier BV; 2023; 8:101318 10.1016/j.esmoop.2023.101318
• Pterostilbene–isothiocyanate reduces miR-21 level by impeding Dicer-mediated processing of pre-miR-21 in 5-fluorouracil and tamoxifen-resistant human breast cancer cell lines Cite
  Kumar V, Haldar S, Saini S, Ghosh S, Dhankhar P, Roy P. Pterostilbene–isothiocyanate reduces miR-21 level by impeding Dicer-mediated processing of pre-miR-21 in 5-fluorouracil and tamoxifen-resistant human breast cancer cell lines. 3 Biotech. Springer Science and Business Media LLC; 2023; 13 10.1007/s13205-023-03582-3
• Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy? Cite
  Karaboyun K, Cavdar E, Irıagac Y, Celebı A, Kapagan T, Gulturk I, et al. Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?. Supportive Care in Cancer. Springer Science and Business Media LLC; 2023; 31 10.1007/s00520-023-07791-7
• Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy Cite
  Nordenskjöld A, Fohlin H, Rosell J, Bengtsson N, Fornander T, Hatschek T, et al. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2856174/v1
• Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors Cite
  Sella T, Zheng Y, Rosenberg SM, Ruddy KJ, Gelber SI, Tamimi RM, et al. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. npj Breast Cancer. Springer Science and Business Media LLC; 2023; 9 10.1038/s41523-023-00529-y
• Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial Cite
  Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, et al. Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 10.1200/jco.22.00577
• Abstract 3902: Glutathione as a potential marker of tamoxifen resistance in breast cancer Cite
  Hamadneh YI, AlWahsh M, Alrawabdeh J, Hergenröder R, Dahabiyeh LA, Hamadneh L. Abstract 3902: Glutathione as a potential marker of tamoxifen resistance in breast cancer. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:3902-3902 10.1158/1538-7445.am2023-3902
• Mammographic Density Reduction is Associated to the Prognosis in Asian Breast Cancer Patients Receiving Hormone Therapy Cite
  Shia W, Lin L, Wu H, Chen C, Chen D. Mammographic Density Reduction is Associated to the Prognosis in Asian Breast Cancer Patients Receiving Hormone Therapy. Cancer Control. SAGE Publications; 2023; 30:107327482311609 10.1177/10732748231160991
• Abstract P1-02-05: Endocrine-targeted therapies modify the gut microbiome affecting responsiveness in ER+ breast cancer Cite
  Arnone A, Wilson AS, Chiba A, Kerr B, Soto-Pantoja DR, Thomas A, et al. Abstract P1-02-05: Endocrine-targeted therapies modify the gut microbiome affecting responsiveness in ER+ breast cancer. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:P1-02-05-P1-02-05 10.1158/1538-7445.sabcs22-p1-02-05
• ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor Cite
  Song C, Kendi AT, Shim JY, Jung D, Kang PS, Lowe VJ, et al. ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor. Breast Cancer. Springer Science and Business Media LLC; 2023; 10.1007/s12282-023-01437-6
• Environmental exposure to cadmium in breast cancer – association with the Warburg effect and sensitivity to tamoxifen Cite
  Tarhonska K, Janasik B, Roszak J, Kowalczyk K, Lesicka M, Reszka E, et al. Environmental exposure to cadmium in breast cancer – association with the Warburg effect and sensitivity to tamoxifen. Biomedicine & Pharmacotherapy. Elsevier BV; 2023; 161:114435 10.1016/j.biopha.2023.114435
• Association between Endocrine Therapy and Cognitive Decline in Older Women with Early Breast Cancer: Findings from the Prospective CLIMB Study Cite
  Baltussen JC, Derks MG, Lemij AA, de Glas NA, Fiocco M, Linthorst-Niers EM, et al. Association between Endocrine Therapy and Cognitive Decline in Older Women with Early Breast Cancer: Findings from the Prospective CLIMB Study. European Journal of Cancer. Elsevier BV; 2023; 10.1016/j.ejca.2023.02.008
• Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea Cite
  Kim D, Oh J, Seok J, Lee HS, Jeon S, Yoon CI. Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea. Diagnostics. MDPI AG; 2023; 13:792 10.3390/diagnostics13040792
• Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer Cite
  Naumann FV, Sweep FCGJ, Adema GJ, Peeters WJM, Martens JWM, Bussink J, et al. Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer. Cancer & Metabolism. Springer Science and Business Media LLC; 2023; 11 10.1186/s40170-023-00304-4
• The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer Cite
  Buijs S, Hoop EO, Braal C, van Rosmalen M, Drooger J, van Rossum-Schornagel Q, et al. The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer. ESMO Open. Elsevier BV; 2023; 8:100786 10.1016/j.esmoop.2023.100786
• Prolonged endocrine therapy in the management of hormone receptor‐positive early‐stage breast cancer: What is the appropriate duration? Cite
  Micha JP, Rettenmaier MA, Bohart RD, Goldstein BH. Prolonged endocrine therapy in the management of hormone receptor‐positive early‐stage breast cancer: What is the appropriate duration?. Journal of Obstetrics and Gynaecology Research. Wiley; 2023; 10.1111/jog.15553
• Factors associated with weight gain after breast cancer: Results from a community-based survey of Australian women Cite
  Ee C, Cave A, Vaddiparthi V, Naidoo D, Boyages J. Factors associated with weight gain after breast cancer: Results from a community-based survey of Australian women. The Breast. Elsevier BV; 2023; 10.1016/j.breast.2023.01.012
• Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea Cite
  Yoon CI, Lee HS, Jeon S, Kim D, Park W. Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 197:603-612 10.1007/s10549-022-06765-3
• Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six‐arm placebo‐controlled trial in healthy women Cite
  Gabrielson M, Hammarström M, Bäcklund M, Bergqvist J, Lång K, Rosendahl AH, et al. Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six‐arm placebo‐controlled trial in healthy women. International Journal of Cancer. Wiley; 2023; 10.1002/ijc.34430
• The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model Cite
  Boszkiewicz K, Moreira H, Sawicka E, Szyjka A, Piwowar A. The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model. Cancers. MDPI AG; 2023; 15:457 10.3390/cancers15020457
• A review of the pharmacodynamic effect of chemo-herbal drug combinations therapy for cancer treatment Cite
  Okem A, Henstra C, Lambert M, Hayeshi R. A review of the pharmacodynamic effect of chemo-herbal drug combinations therapy for cancer treatment. Medicine in Drug Discovery. Elsevier BV; 2023; 17:100147 10.1016/j.medidd.2022.100147
• Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer Cite
  Ryu K, Kim MS, Lee JY, Nam S, Jeong HG, Kim T, et al. Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2022; 5:e2243951 10.1001/jamanetworkopen.2022.43951
• Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study Cite
  Houvenaeghel G, de Nonneville A, Cohen M, Classe J, Reyal F, Mazouni C, et al. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. European Journal of Cancer. Elsevier BV; 2022; 176:58-69 10.1016/j.ejca.2022.08.027
• Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration Cite
  Kara F, Lohse CM, Castillo AM, Tosakulwong N, Lesnick TG, Jack CR, et al. Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration. Cancer Medicine. Wiley; 2022; 10.1002/cam4.5175
• Time to Mammographic Density Decrease After Exposure to Tamoxifen Cite
  Bäcklund M, Eriksson M, Hammarström M, Thoren L, Bergqvist J, Margolin S, et al. Time to Mammographic Density Decrease After Exposure to Tamoxifen. The Oncologist. Oxford University Press (OUP); 2022; 27:e601-e603 10.1093/oncolo/oyac104
• Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial Cite
  Johansson A, Dar H, van ’t Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, et al. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.02844
• Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis Cite
  Zeng E, He W, Smedby KE, Czene K. Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2022; 20:683-689.e2 10.6004/jnccn.2021.7116
• Low-dose tamoxifen for breast cancer prevention in patients with ductal carcinoma in situ (DCIS) and atypical lesions: A real-world experience. Cite
  Patel R, Jin C, Tiersten A. Low-dose tamoxifen for breast cancer prevention in patients with ductal carcinoma in situ (DCIS) and atypical lesions: A real-world experience.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:e12537-e12537 10.1200/jco.2022.40.16_suppl.e12537
• Weight Gain after Hormone Receptor-Positive Breast Cancer Cite
  Goyal A, Milner GE, Cimino-Mathews A, Visvanathan K, Wolff AC, Sharma D, et al. Weight Gain after Hormone Receptor-Positive Breast Cancer. Current Oncology. MDPI AG; 2022; 29:4090-4103 10.3390/curroncol29060326
• Breast density reduction as a predictor for prognosis in premenopausal women with hormone receptor–positive breast cancer: A retrospective analysis of the ASTRRA study. Cite
  Bae SJ, Kim H, Ryu JM, Park S, Lee E, Im S, et al. Breast density reduction as a predictor for prognosis in premenopausal women with hormone receptor–positive breast cancer: A retrospective analysis of the ASTRRA study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:531-531 10.1200/jco.2022.40.16_suppl.531
• 398 Does tamoxifen therapy increases occurence of endometrium pathology? Cite
  Wojda K, Kalukiewicz A, Bobeff K, Sieroszewski P. 398 Does tamoxifen therapy increases occurence of endometrium pathology?. European Journal of Obstetrics & Gynecology and Reproductive Biology. Elsevier BV; 2022; 270:e104-e105 10.1016/j.ejogrb.2021.11.339
• Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer? Cite
  Ju UC, Kang WD, Kim SM. Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer?. European Journal of Gynaecological Oncology. IMR Press; 2022; 43:169-174 10.31083/j.ejgo4302022
• Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy Cite
  Matar R, Sevilimedu V, Gemignani ML, Morrow M. Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-022-11728-5
• EGFR inhibition reverses epithelial‑mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells Cite
  Takeda T, Tsubaki M, Matsuda T, Kimura A, Jinushi M, Obana T, et al. EGFR inhibition reverses epithelial‑mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. Oncology Reports. Spandidos Publications; 2022; 47 10.3892/or.2022.8320
• Does the toxicity of endocrine therapy persist into long-term survivorship? – Patient-reported outcome results from a follow-up study beyond a 10-year-survival Cite
  Albertini C, Oberguggenberger A, Sztankay M, Egle D, Giesinger J, Meraner V, et al. Does the toxicity of endocrine therapy persist into long-term survivorship? – Patient-reported outcome results from a follow-up study beyond a 10-year-survival. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1526913/v1
• Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer Cite
  Jiang Y, Qian T, Li S, Xie Y, Tao M. Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer. Annals of Translational Medicine. AME Publishing Company; 2022; 10:366-366 10.21037/atm-22-795
• Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease Cite
  DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, et al. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clinical Cancer Research. American Association for Cancer Research (AACR); 2021; 27:3576-3583 10.1158/1078-0432.ccr-20-4213
• Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen Cite
  Bychkovsky B, Laws A, Katlin F, Hans M, Knust Graichen M, Pace LE, et al. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06577-5
• Alteration in glucose metabolism in the brain associated with tamoxifen treatment: Study in postmenopausal animal model Cite
  Koerich S, Silva FC, Itinose AM, Bellozi PMQ, Sandrini F, Schneider SCS, et al. Alteration in glucose metabolism in the brain associated with tamoxifen treatment: Study in postmenopausal animal model. Toxicology and Applied Pharmacology. Elsevier BV; 2022; 442:116002 10.1016/j.taap.2022.116002
• Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status Cite
  Hills RK, Oesterreich S, Metzger O, Dabbs D, Pan H, Braybrooke J, et al. Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:PD14-08-PD14-08 10.1158/1538-7445.sabcs21-pd14-08
• Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α Cite
  Chen Y, Zhang J, Zhang M, Song Y, Zhang Y, Fan S, et al. Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α. Clinical and Translational Medicine. Wiley; 2021; 11 10.1002/ctm2.577
• No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach Cite
  Clèries R, Buxó M, Vilardell M, Ameijide A, Martínez JM, Font R, et al. No Excess Mortality up to 10 Years in Early Stages of Breast Cancer in Women Adherent to Oral Endocrine Therapy: A Probabilistic Graphical Modeling Approach. International Journal of Environmental Research and Public Health. MDPI AG; 2022; 19:3605 10.3390/ijerph19063605
• Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study Cite
  Moskalewicz A, Di Tomaso A, Kachura JJ, Scime S, Nisenbaum R, Lee R, et al. Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study. Current Oncology. MDPI AG; 2022; 29:1813-1827 10.3390/curroncol29030149
• Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models Cite
  Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, et al. Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-022-00397-y
• Diethylhexyl Phthalate and Bisphenol A Promote Vincristine and Tamoxifen Resistance in Vitro Cite
  Uyar R, Yurdakok-Dikmen B, Turgut Y, Filazi A. Diethylhexyl Phthalate and Bisphenol A Promote Vincristine and Tamoxifen Resistance in Vitro. Chemical Research in Toxicology. American Chemical Society (ACS); 2022; 10.1021/acs.chemrestox.2c00002
• De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort Cite
  Cai Y, Shao Z, Yu K. De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort. Cancer. Wiley; 2022; 10.1002/cncr.34155
• Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy Cite
  Fu F, Yu L, Zeng B, Chen M, Guo W, Chen L, et al. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy. JAMA Network Open. American Medical Association (AMA); 2022; 5:e2145934 10.1001/jamanetworkopen.2021.45934
• Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Cite
  Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. Elsevier BV; 2022; 10.1016/s1470-2045(21)00758-0
• Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go??? Cite
  Jacobs CF, Soesan M, Sonke GS. Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06505-z
• Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen Cite
  HENRIQUES PALMA GB, KAUR M. Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen. Anticancer Research. Anticancer Research USA Inc.; 2021; 42:565-579 10.21873/anticanres.15514
• Hysteroscopic Endometrial Resection in Symptomatic Tamoxifen Treated Women for Breast Cancer Can Provide Both Definitive Diagnosis and Effective Long-term Therapy Cite
  Vilos GA, Alzawawi N, Oraif A, Lam JS, Badeghiesh A, Abu-Rafea B, et al. Hysteroscopic Endometrial Resection in Symptomatic Tamoxifen Treated Women for Breast Cancer Can Provide Both Definitive Diagnosis and Effective Long-term Therapy. Journal of Obstetrics and Gynaecology Canada. Elsevier BV; 2021; 10.1016/j.jogc.2021.12.007
• Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen Cite
  HENRIQUES PALMA GB, KAUR M. Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen. Anticancer Research. Anticancer Research USA Inc.; 2021; 42:565-579 10.21873/anticanres.15514
• The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials Cite
  Alomar SA, Găman M, Prabahar K, Arafah OA, Almarshood F, Baradwan S, et al. The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials. Experimental Gerontology. Elsevier BV; 2022; 159:111680 10.1016/j.exger.2021.111680
• Insights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents Cite
  Farooq J, Sultana R, Taj T, Asdaq SMB, Alsalman AJ, Mohaini MA, et al. Insights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents. Molecules. MDPI AG; 2021; 27:226 10.3390/molecules27010226
• Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor Cite
  Hwang K, Suh YJ, Park C, Lee YJ, Kim JY, Jung JH, et al. Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor. The Oncologist. Wiley; 2021; 26 10.1002/onco.13938
• Low concentrations of 17β‐estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor‐mediated signaling pathways Cite
  Xu Z, Zhao D, Zheng X, Huang B, Pan X, Xia X. Low concentrations of 17β‐estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor‐mediated signaling pathways. Environmental Toxicology. Wiley; 2021; 10.1002/tox.23417
• Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study Cite
  Collin LJ, Maliniak ML, Cronin-Fenton DP, Ahern TP, Christensen KB, Ulrichsen SP, et al. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study. Breast Cancer Research. Springer Science and Business Media LLC; 2021; 23 10.1186/s13058-021-01480-1
• EPV112/#318 Uterine carcinosarcoma following tamoxifen therapy for breast cancer: a series of 11 cases Cite
  Ben Hamida K, Naija L, Ghalleb M, Bouida M, Chargui R, Rahal K. EPV112/#318 Uterine carcinosarcoma following tamoxifen therapy for breast cancer: a series of 11 cases. E-Posters. BMJ Publishing Group Ltd; 2021; 10.1136/ijgc-2021-igcs.182
• Revisiting the Anticancer Drug–Food Interactions Cite
  Gacche RN. Revisiting the Anticancer Drug–Food Interactions. Dietary Research and Cancer. Springer Singapore; 2021;:113-120 10.1007/978-981-16-6050-4_11
• Evaluation of Adjuvant Radiation and Endocrine Therapy in Elderly Patients with Early-Stage Breast Cancer Cite
  Ma S, Yu B, Oladeru O, Bartl A, Farrugia M, Fekrmandi F, et al. Evaluation of Adjuvant Radiation and Endocrine Therapy in Elderly Patients with Early-Stage Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2021; 111:e207-e208 10.1016/j.ijrobp.2021.07.734
• Adherence to Endocrine Therapy Predicts Short-Term Clinical Outcomes for Postmenopausal Women With Luminal B but Not Luminal A Breast Cancer Cite
  Fahey M, Mills M, Liveringhouse C, Ronica N, Diaz R. Adherence to Endocrine Therapy Predicts Short-Term Clinical Outcomes for Postmenopausal Women With Luminal B but Not Luminal A Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2021; 111:e206 10.1016/j.ijrobp.2021.07.730
• Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions Cite
  Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, et al. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions. Nutrients. MDPI AG; 2021; 13:3730 10.3390/nu13113730
• Is it necessary to measure basal serum lipid levels in cancer patients prior to tamoxifen treatment? Cite
  Sütcüoğlu O, Yazıcı O, Özet A. Is it necessary to measure basal serum lipid levels in cancer patients prior to tamoxifen treatment?. Future Oncology. Future Medicine Ltd; 2021; 10.2217/fon-2021-1107
• Inhibition of Estrogen Receptor Signaling as a Strategy for Radiosensitization of ER+ Breast Cancers Cite
  Michmerhuizen A, Pesch A, Schwartz R, Wilder-Romans K, Liu M, Harold A, et al. Inhibition of Estrogen Receptor Signaling as a Strategy for Radiosensitization of ER+ Breast Cancers. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2021; 111:e253 10.1016/j.ijrobp.2021.07.842
• Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions Cite
  Sella T, Ruddy KJ, Carey LA, Partridge AH. Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. JCO Oncology Practice. American Society of Clinical Oncology (ASCO); 2021; 10.1200/op.21.00482
• Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review Cite
  Bradbury M, Hutton B, Beltran-Bless A, AlZahrani M, Lariviere T, Fernandes R, et al. Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.10.003
• Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years Cite
  Riyad AY, Elkhodary DA, Elghamry WRF, Zaki IAKM. Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years. QJM: An International Journal of Medicine. Oxford University Press (OUP); 2021; 114 10.1093/qjmed/hcab103.010
• Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival Cite
  Taroeno-Hariadi KW, Putra YR, Choridah L, Widodo I, Hardianti MS, Aryandono T. Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival. Journal of Breast Cancer. Korean Breast Cancer Society; 2021; 24 10.4048/jbc.2021.24.e41
• Concomitant diagnosis of Endometrial and Breast Cancer - Does the sequence matters? Cite
  Stern T, Peleg Hasson S, Saad A, Levanon K, Michaan N, Laskov I, et al. Concomitant diagnosis of Endometrial and Breast Cancer - Does the sequence matters?. Gynecologic Oncology Reports. Elsevier BV; 2021;:100863 10.1016/j.gore.2021.100863
• Role of estrogen receptor coregulators in endocrine resistant breast cancer Cite
  Altwegg KA, Vadlamudi RK. Role of estrogen receptor coregulators in endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy. Open Exploration Publishing; 2021;:385-400 10.37349/etat.2021.00052
• Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer Cite
  Jiang R, Sun Y, Chen X, Shi P. Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06385-3
• Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells Cite
  Steifensand F, Gallwas J, Bauerschmitz G, Gründker C. Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells. Cells. MDPI AG; 2021; 10:2398 10.3390/cells10092398
• Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review Cite
  Jebahi F, Sharma S, Bloss JE, Wright HH. Effects of tamoxifen on cognition and language in women with breast cancer: A systematic search and a scoping review. Psycho-Oncology. Wiley; 2021; 30:1262-1277 10.1002/pon.5696
• Breast cancer endocrine therapy promotes weight gain with distinct adipose tissue effects in lean and obese female mice Cite
  Scalzo RL, Foright RM, Hull SE, Knaub LA, Johnson-Murguia S, Kinanee F, et al. Breast cancer endocrine therapy promotes weight gain with distinct adipose tissue effects in lean and obese female mice. Endocrinology. The Endocrine Society; 2021; 10.1210/endocr/bqab174
• Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB Cite
  Nagalingam A, Siddharth S, Parida S, Muniraj N, Avtanski D, Kuppusamy P, et al. Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00314-9
• Cognitive Dysfunction after Heart Disease: A Manifestation of the Heart-Brain Axis Cite
  Xu C, Tao X, Ma X, Zhao R, Cao Z. Cognitive Dysfunction after Heart Disease: A Manifestation of the Heart-Brain Axis. Oxidative Medicine and Cellular Longevity. Hindawi Limited; 2021; 2021:1-10 10.1155/2021/4899688
• Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes Cite
  Cao L, Sugumar K, Keller E, Li P, Rock L, Simpson A, et al. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-10459-3
• The influence of hormone therapy on secondary diabetes mellitus in breast cancer: a meta-analysis Cite
  Ye F, Wen J, Yang A, Wang Y, Li N, Yu P, et al. The influence of hormone therapy on secondary diabetes mellitus in breast cancer: a meta-analysis. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.06.014
• Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment Cite
  Al-jubori AA, Sulaiman GM, Tawfeeq AT, Mohammed HA, Khan RA, Mohammed SAA. Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment. Pharmaceutics. MDPI AG; 2021; 13:1098 10.3390/pharmaceutics13071098
• CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Drug Response: A Secondary Analyses of the KARISMA Trial Cite
  He W, Eriksson M, Eliasson E, Grassmann F, Bäcklund M, Gabrielson M, et al. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Drug Response: A Secondary Analyses of the KARISMA Trial. Annals of Oncology. Elsevier BV; 2021; 10.1016/j.annonc.2021.07.005
• Association between Endocrine Therapy and Weight Gain after Breast Cancer Diagnosis among Japanese Patients: A Retrospective Cohort Study Cite
  Okumatsu K, Yamauchi H, Kotake R, Gosho M, Nakata Y. Association between Endocrine Therapy and Weight Gain after Breast Cancer Diagnosis among Japanese Patients: A Retrospective Cohort Study. Medical Sciences. MDPI AG; 2021; 9:50 10.3390/medsci9030050
• Luteolin mitigates tamoxifen-associated fatty liver and cognitive impairment in rats by modulating beta-catenin Cite
  El-Asfar RK, El-Derany MO, Sallam AM, Wahdan SA, El-Demerdash E, Sayed SA, et al. Luteolin mitigates tamoxifen-associated fatty liver and cognitive impairment in rats by modulating beta-catenin. European Journal of Pharmacology. Elsevier BV; 2021; 908:174337 10.1016/j.ejphar.2021.174337
• Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR Cite
  Fernández-Suárez ME, Daimiel L, Villa-Turégano G, Pavón MV, Busto R, Escolà-Gil JC, et al. Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR. Biomedicine & Pharmacotherapy. Elsevier BV; 2021; 141:111871 10.1016/j.biopha.2021.111871
• Molecular Genetic Characterization of a Subset of Women With Early Breast Cancer Followed Up for 25 Years in the Stockholm Tamoxifen Clinical Trial Cite
  Burton RC. Molecular Genetic Characterization of a Subset of Women With Early Breast Cancer Followed Up for 25 Years in the Stockholm Tamoxifen Clinical Trial. JAMA Network Open. American Medical Association (AMA); 2021; 4:e2115227 10.1001/jamanetworkopen.2021.15227
• Abstract 737: Estrogen receptor inhibition with tamoxifen mediates radiosensitization of ER+ breast cancer models Cite
  Michmerhuizen AR, Pesch AM, Schwartz R, Wilder-Romans K, Liu M, Azaria R, et al. Abstract 737: Estrogen receptor inhibition with tamoxifen mediates radiosensitization of ER+ breast cancer models. Endocrinology. American Association for Cancer Research; 2021; 10.1158/1538-7445.am2021-737
• Recombinant human Erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells Cite
  Shujaa Edin HY, AL-Haj NA, Rasedee A, Banu Alitheen N, Abdul Kadir A, Wun How C, et al. Recombinant human Erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells. Saudi Journal of Biological Sciences. Elsevier BV; 2021; 10.1016/j.sjbs.2021.05.043
• Vaginal Laser Therapy for Genitourinary Syndrome of Menopause – Systematic Review Cite
  Mension E, Alonso I, Tortajada M, Matas I, Gómez S, Ribera L, et al. Vaginal Laser Therapy for Genitourinary Syndrome of Menopause – Systematic Review. Maturitas. Elsevier BV; 2021; 10.1016/j.maturitas.2021.06.005
• Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study Cite
  Mamguem Kamga A, Billa O, Ladoire S, Poillot M, Jolimoy G, Roignot P, et al. Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study. The Breast. Elsevier BV; 2021; 10.1016/j.breast.2021.06.003
• Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients Cite
  Dackus GM, Jóźwiak K, Sonke GS, van der Wall E, van Diest PJ, Siesling S, et al. Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab091
• The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration Cite
  Djahansouzi S, Hanstein B, Rein D, Clees M, Rath W. The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration. Cancer Reports. Wiley; 2021; 10.1002/cnr2.1431
• Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway Cite
  Kwon Y, Nam K, Kim S. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. Biochemical Pharmacology. Elsevier BV; 2021;:114635 10.1016/j.bcp.2021.114635
• Effects of Adjuvant Endocrine Therapy Adherence and Radiation on Recurrence and Survival Among Older Women with Early-Stage Breast Cancer Cite
  Showalter SL, Meneveau MO, Keim-Malpass J, Camacho TF, Squeo G, Anderson RT. Effects of Adjuvant Endocrine Therapy Adherence and Radiation on Recurrence and Survival Among Older Women with Early-Stage Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-10064-4
• Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States Cite
  Faiz AS, Guo S, Kaveney A, Philipp CS. Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States. Blood Coagulation & Fibrinolysis. Ovid Technologies (Wolters Kluwer Health); 2021; Publish Ahead of Print 10.1097/mbc.0000000000001043
• 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer Cite
  Dar H, Johansson A, Nordensköljd A, Iftimi A, Yau C, Perez-Tenorio G, et al. 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer. Annals of Oncology. Elsevier BV; 2021; 32:S23 10.1016/j.annonc.2021.03.020
• Association of Endocrine Therapy and Dementia in Women with Breast Cancer Cite
  Thompson MR, Niu J, Lei X, Nowakowska M, Wehner MR, Giordano SH, et al. Association of Endocrine Therapy and Dementia in Women with Breast Cancer. Breast Cancer: Targets and Therapy. Informa UK Limited; 2021; Volume 13:219-224 10.2147/bctt.s300455
• Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial Cite
  Eriksson M, Eklund M, Borgquist S, Hellgren R, Margolin S, Thoren L, et al. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021;:JCO.20.02598 10.1200/jco.20.02598
• Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data Cite
  Lailler G, Memoli V, Le Bihan Benjamin C, Ben Diane M, Lauzier S, Mancini J, et al. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.01.007
• Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer Cite
  Menendez JA, Papadimitropoulou A, Vander Steen T, Cuyàs E, Oza-Gajera BP, Verdura S, et al. Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers. MDPI AG; 2021; 13:1132 10.3390/cancers13051132
• Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies Cite
  Sneha S, Baker SC, Green A, Storr S, Aiyappa R, Martin S, et al. Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. Biomedicines. MDPI AG; 2021; 9:290 10.3390/biomedicines9030290
• Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions Cite
  Wu S, Sharma S, Wu K, Tyagi A, Zhao D, Deshpande RP, et al. Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions. Breast Cancer Research. Springer Science and Business Media LLC; 2021; 23 10.1186/s13058-021-01412-z
• Fractional CO₂ vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors Cite
  Siliquini GP, Bounous VE, Novara L, Giorgi M, Bert F, Biglia N. Fractional CO₂ vaginal laser for the genitourinary syndrome of menopause in breast cancer survivors. The Breast Journal. Wiley; 2021; 10.1111/tbj.14211
• Distribution of dyslipidemia in Chinese early breast cancer patients at diagnosis and comparison of dyslipidemia incidence following different endocrine therapies: a population-based cohort study Cite
  Wang J, Yin J, Qiu J, Jiang J, Hu Y, Zheng H, et al. Distribution of dyslipidemia in Chinese early breast cancer patients at diagnosis and comparison of dyslipidemia incidence following different endocrine therapies: a population-based cohort study. Research Square; 2021; 10.21203/rs.3.rs-298866/v1
• Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial Cite
  Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, et al. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06168-w
• Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review Cite
  Mansouri S, Mokhtari-Hesari P, Naghavi-al-Hosseini F, Seyednejad SA, Majidzadeh-A K, Moradi-kalbolandi S, et al. Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review. Pharmacological Reports. Springer Science and Business Media LLC; 2021; 10.1007/s43440-021-00237-z
• Abstract PS19-28: Thymoquinone and tamoxifen co-treatment synergistically inhibit proliferation, invasion and induce apoptosis in human breast cancer cell lines in vitro and in vivo Cite
  Yahiya I, Helmy H, Sultan A. Abstract PS19-28: Thymoquinone and tamoxifen co-treatment synergistically inhibit proliferation, invasion and induce apoptosis in human breast cancer cell lines in vitro and in vivo. Poster Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-ps19-28
• Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives Cite
  Cocetta V, Quagliariello V, Fiorica F, Berretta M, Montopoli M. Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives. International Journal of Molecular Sciences. MDPI AG; 2021; 22:2049 10.3390/ijms22042049
• Abstract PD12-07: Incidences of endometrial events and frequencies of endometrial invasive diagnostic procedures in breast cancer survivors on tamoxifen: A nationwide study Cite
  Choi S, Jeong Jh, Jung J, Lee YJ, Lee JW, Ko BS, et al. Abstract PD12-07: Incidences of endometrial events and frequencies of endometrial invasive diagnostic procedures in breast cancer survivors on tamoxifen: A nationwide study. Poster Spotlight Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-pd12-07
• Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ Cite
  Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, et al. Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. General Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-gs2-02
• Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men Cite
  Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Strittmatter H, et al. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men. JAMA Oncology. American Medical Association (AMA); 2021; 10.1001/jamaoncol.2020.7442
• Implications of Antidepressants Use in Breast Cancer: A Brief Review Cite
  Strazzanti A, Martorana F, Intagliata E, Lanzafame K, Pavone G, Mauro S, et al. Implications of Antidepressants Use in Breast Cancer: A Brief Review. Surgery, Gastroenterology and Oncology. Celsius Publishing House; 2020; 25:229 10.21614/sgo-25-5-229
• A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature Cite
  Avram CM, Brumbach BH, Hiller AL. A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature. Movement Disorders. Wiley; 2021; 10.1002/mds.28471
• Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse Cite
  Sanchez-Spitman AB, Swen JJ, Dezentjé VO, Moes DJAR, Gelderblom H, Guchelaar HJ. Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-020-79972-x
• Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer Cite
  Robertson JF, Paridaens RJ, Lichfield J, Bradbury I, Campbell C. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. European Journal of Cancer. Elsevier BV; 2021; 145:19-28 10.1016/j.ejca.2020.11.038
• The immunomodulatory effects of endocrine therapy in breast cancer Cite
  Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, et al. The immunomodulatory effects of endocrine therapy in breast cancer. Journal of Experimental & Clinical Cancer Research. Springer Science and Business Media LLC; 2021; 40 10.1186/s13046-020-01788-4
• Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer Cite
  Goldfarb SB, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, et al. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05933-7
• Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells Cite
  Hamadneh L, Abuarqoub R, Alhusban A, Bahader M. Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells. Scientific Reports. Springer Science and Business Media LLC; 2020; 10 10.1038/s41598-020-78833-x
• Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen Cite
  Romero SA, Young K, Hickey M, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews. Wiley; 2020; 10.1002/14651858.cd007245.pub4
• Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cite
  Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, et al. Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. Wiley; 2020; 10.1002/cncr.33318
• Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells Cite
  López-Sánchez LM, Mena R, Guil-Luna S, Mantrana A, Peñarando J, Toledano-Fonseca M, et al. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells. Laboratory Investigation. Springer Science and Business Media LLC; 2020; 10.1038/s41374-020-00507-z
• Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study Cite
  Schiza A, Mauri D, Fredriksson I, Anna-Karin Wennstig , Valachis A. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-06022-5
• The apple dihydrochalcone phloretin suppresses growth and improves chemosensitivity of breast cancer cells via inhibition of cytoprotective autophagy Cite
  Chen M, Gowd V, Wang M, Chen F, Cheng K. The apple dihydrochalcone phloretin suppresses growth and improves chemosensitivity of breast cancer cells via inhibition of cytoprotective autophagy. Food & Function. Royal Society of Chemistry (RSC); 2020; 10.1039/d0fo02362k
• Separate and simultaneous binding of tamoxifen and estradiol to human serum albumin: Spectroscopic and molecular modeling investigations Cite
  Moradi N, Ashrafi-Kooshk MR, Chamani J, Shackebaei D, Norouzi F. Separate and simultaneous binding of tamoxifen and estradiol to human serum albumin: Spectroscopic and molecular modeling investigations. Journal of Molecular Liquids. Elsevier BV; 2018; 249:1083-1096 10.1016/j.molliq.2017.11.056
• The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy Cite
  Dell’Acqua G, Richards A, Thornton MJ. The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy. Nutrients. MDPI AG; 2020; 12:3537 10.3390/nu12113537
• Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction Cite
  Parihar V, Rogers A, Blain AM, Zacharias SRK, Patterson LL, Siyam MA. Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction. Journal of Pharmacy Practice. SAGE Publications; 2020;:089719002097220 10.1177/0897190020972208
• Coffee decoction enhances tamoxifen proapoptotic activity on MCF-7 cells Cite
  Funakoshi-Tago M, Tago K, Li C, Hokimoto S, Tamura H. Coffee decoction enhances tamoxifen proapoptotic activity on MCF-7 cells. Scientific Reports. Springer Science and Business Media LLC; 2020; 10 10.1038/s41598-020-76445-z
• Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer Cite
  Turnbull AK, Patel S, Martinez-Perez C, Rigg A, Oikonomidou O. Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05951-5
• Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments Cite
  Hatono M, Ikeda H, Suzuki Y, Kajiwara Y, Kawada K, Tsukioki T, et al. Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05957-z
• Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years Cite
  Brentnall AR, Warren R, Harkness EF, Astley SM, Wiseman J, Fox J, et al. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-01340-4
• Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women Cite
  Nayyar A, Strassle PD, Iles K, Jameison D, Jadi J, McGuire KP, et al. Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:4853-4860 10.1245/s10434-020-08945-1
• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Cite
  Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3987-3998 10.1200/jco.20.02514
• Bioinformatic analysis reveals the molecular targets of tangeretin in overcoming the resistance of breast cancer to tamoxifen Cite
  Hermawan A, Putri H, Ikawati M. Bioinformatic analysis reveals the molecular targets of tangeretin in overcoming the resistance of breast cancer to tamoxifen. Gene Reports. Elsevier BV; 2020; 21:100884 10.1016/j.genrep.2020.100884
• Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer Cite
  Lee KT, Jacobs L, Walsh EM, Stearns V, Segal JB. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:965-975 10.1007/s10549-020-05910-0
• Tamoxifen and Endometrial Cancer: A Janus-Headed Drug Cite
  Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers. MDPI AG; 2020; 12:2535 10.3390/cancers12092535
• Association of endocrine therapy with overall survival in women with hormone receptor‐positive, HER2‐negative, node‐negative breast cancer of favorable histology Cite
  Oladeru OT, Singh AK, Ma SJ. Association of endocrine therapy with overall survival in women with hormone receptor‐positive, HER2‐negative, node‐negative breast cancer of favorable histology. The Breast Journal. Wiley; 2020; 26:2006-2010 10.1111/tbj.13995
• Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen Cite
  Braal CL, Hussaarts KGAM, Seuren L, Oomen-de Hoop E, de Bruijn P, Buck SAJ, et al. Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:107-113 10.1007/s10549-020-05829-6
• Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database Cite
  Nahleh ZA, Elimimian EB, Elson LC, Hobbs B, Wei W, Blake CN. Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database. Breast Cancer: Basic and Clinical Research. SAGE Publications; 2020; 14:117822342094569 10.1177/1178223420945694
• Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer Cite
  Yoo J, Lim YS, Kim MS, Lee B, Kim B, Kim Z, et al. Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0236506 10.1371/journal.pone.0236506
• Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies Cite
  Jeon J, Kim SE, Lee D, Choi D. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:125-130 10.1007/s10549-019-05448-w
• Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells Cite
  LEE SJ, JEONG J, LEE IH, LEE J, JUNG JH, PARK HY, et al. Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells. Anticancer Research. International Institute of Anticancer Research; 2019; 39:751-758 10.21873/anticanres.13172
• Curcumin Increases Anti-Cancer Activity of Tamoxifen in MCF-7 Breast Cancer Cells Through the Suppression of MDR1 mRNA Expression Cite
  Louisa M, Sugiarti L, Kurniawan SV, Wanandi SI. Curcumin Increases Anti-Cancer Activity of Tamoxifen in MCF-7 Breast Cancer Cells Through the Suppression of MDR1 mRNA Expression. Advanced Science Letters. American Scientific Publishers; 2017; 23:6838-6840 10.1166/asl.2017.9412
• Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors Cite
  Raghavendra A, Sinha AK, Valle-Goffin J, Shen Y, Tripathy D, Barcenas CH. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors. Clinical Breast Cancer. Elsevier BV; 2018; 18:e7-e13 10.1016/j.clbc.2017.11.006
• Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo Cite
  Han N, Zhou Q, Huang Q, Liu K. Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo. Biomedicine & Pharmacotherapy. Elsevier BV; 2017; 89:827-837 10.1016/j.biopha.2017.01.084
• Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin Cite
  Choi JS, Cho YA, Lee W. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Govi-Verlag Pharmazeutischer Verlag GmbH; 2012;:124-130. 10.1691/ph.2012.1099
• Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review Cite
  Nyrop KA, Deal AM, Lee JT, Muss HB, Choi SK, Dixon S, et al. Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 162:375-388 10.1007/s10549-017-4106-y
• Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway Cite
  Geng C, Li J, Ding F, Wu G, Yang Q, Sun Y, et al. Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway. Biochemical and Biophysical Research Communications. Elsevier BV; 2016; 473:147-153 10.1016/j.bbrc.2016.03.067
• Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice Cite
  Theile D, Hohmann N, Kiemel D, Gattuso G, Barreca D, Mikus G, et al. Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice. European Journal of Pharmaceutical Sciences. Elsevier BV; 2017; 97:247-256 10.1016/j.ejps.2016.11.021
• Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? Cite
  Bailey DG, Dresser G, Arnold JMO. Grapefruit–medication interactions: Forbidden fruit or avoidable consequences?. Canadian Medical Association Journal. CMA Joule Inc.; 2012; 185:309-316 10.1503/cmaj.120951
• Tamoxifen and CYP2D6: A Contradiction of Data Cite
  Hertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: A Contradiction of Data. The Oncologist. Wiley; 2012; 17:620-630 10.1634/theoncologist.2011-0418
• In vitrometabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4 Cite
  Li J, Gödecke T, Chen S, Imai A, Lankin DC, Farnsworth NR, et al. In vitrometabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica. Informa UK Limited; 2011; 41:1021-1030 10.3109/00498254.2011.603385
• Tamoxifen represses alcohol-induced transcription of RNA polymerase III-dependent genes in breast cancer cells Cite
  Zhong Q, Shi G, Zhang Q, Lu L, Levy D, Zhong S. Tamoxifen represses alcohol-induced transcription of RNA polymerase III-dependent genes in breast cancer cells. Oncotarget. Impact Journals, LLC; 2014; 5:12410-12417 10.18632/oncotarget.2678
• CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Cite
  Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:441-451 10.1093/jnci/djs125
• Breast cancer in pregnancy Cite
  Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. The Lancet. Elsevier BV; 2012; 379:570-579 10.1016/s0140-6736(11)61092-1
• Undesirable Effects of Citrus Juice on the Pharmacokinetics of Drugs Cite
  Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable Effects of Citrus Juice on the Pharmacokinetics of Drugs. Drug Safety. Springer Science and Business Media LLC; 2012; 28:677-694 10.2165/00002018-200528080-00003
• Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9 Cite
  Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, et al. Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9. Molecules. MDPI AG; 2013; 18:701-720 10.3390/molecules18010701
• Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial Cite
  Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, et al. Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prevention Research. American Association for Cancer Research (AACR); 2011; 4:1393-1400 10.1158/1940-6207.capr-11-0172
• Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3a4 activity: comparison with grapefruit juice Cite
  Bailey D. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3a4 activity: comparison with grapefruit juice. Clinical Pharmacology & Therapeutics. Wiley; 2003; 73:529-537 10.1016/s0009-9236(03)00051-1
• The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women. Cite
  Holmes CE, Jasielec J, Levis JE, Skelly J, Muss HB. The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:679-679 10.1200/jco.2010.28.15_suppl.679
• Second cancers after breast cancer treatment Cite
  Matesich SMA, Shapiro CL. Second cancers after breast cancer treatment. Seminars in Oncology. Elsevier BV; 2003; 30:740-748 10.1053/j.seminoncol.2003.08.022
• Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen Cite
  Bertelli G, Hall E, Ireland E, Snowdon C, Jassem J, Drosik K, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. Annals of Oncology. Elsevier BV; 2010; 21:498-505 10.1093/annonc/mdp358
• Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients Cite
  Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1287-1293 10.1200/jco.2009.25.7246
• Salubrious effect of vitamin C and vitamin E on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels Cite
  Ramesh Babu J, Sundravel S, Arumugam G, Renuka R, Deepa N, Sachdanandam P. Salubrious effect of vitamin C and vitamin E on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels. Cancer Letters. Elsevier BV; 2000; 151:1-5 10.1016/s0304-3835(99)00340-7
• Curcumin Modulates Tamoxifen Response in Resistant Breast Cancer Cells. Cite
  De Gasperi M, Cavazos D, deGraffenried L. Curcumin Modulates Tamoxifen Response in Resistant Breast Cancer Cells.. Poster Session Abstracts. American Association for Cancer Research; 2009; 10.1158/0008-5472.sabcs-09-3098